Berkeley Lights to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Rhea-AI Summary

Berkeley Lights, Inc. (Nasdaq: BLI) will report its fourth quarter and full year 2022 financial results on February 23, 2023, after market close. A conference call will be held at 1:30 PM PT (4:30 PM ET) to discuss these results. The webcast will be accessible in the Investors section of their website and will be archived for later listening.

Berkeley Lights specializes in life sciences tools that accelerate the commercialization of biotherapeutics and cell-based products. Their platform provides extensive data on single cells, aiming to set an industry standard.

Positive

• Scheduled release of fourth quarter and full year 2022 financial results, indicating transparency.
• Webcast of results allows for real-time investor engagement.

Negative

• None.

EMERYVILLE, Calif., Feb. 13, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced that the Company will be reporting financial results for the fourth quarter and full year 2022 after market on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.  

Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay after the event. 

About Berkeley Lights 

Berkeley Lights is a life sciences tools company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect® chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Forward-Looking Statements 

To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/berkeley-lights-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023-301745565.html

SOURCE Berkeley Lights, Inc.

FAQ

When is Berkeley Lights reporting its financial results for 2022?

Berkeley Lights will report its financial results on February 23, 2023.

What time is the conference call for Berkeley Lights' financial results?

The conference call will take place at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Where can I listen to the Berkeley Lights financial results webcast?

The webcast can be accessed in the 'Investors' section of Berkeley Lights' website.

What is the focus of Berkeley Lights as a company?

Berkeley Lights focuses on enabling rapid development and commercialization of biotherapeutics and cell-based products.